Low and sustained doses of erythropoietin prevent preterm infants from intraventricular hemorrhage

In addition to its hematopoietic function, erythropoietin (EPO) has demonstrated neuroprotective properties in preclinical studies, particularly in cases of reduced oxygenation or ischemia in the neonatal brain. While these findings have sparked optimism for its potential clinical application, the e...

Full description

Saved in:

Bibliographic Details
Published in:	Respiratory physiology & neurobiology Vol. 331; p. 104363
Main Authors:	Arias Fernández, Diana Andrea, Romero Diaz, Héctor Alfonso, Figueroa Garnica, Alan David, Iturri-Soliz, Pablo, Arias-Reyes, Christian, Schneider Gasser, Edith Mariane, Soliz, Jorge
Format:	Journal Article
Language:	English
Published:	Elsevier B.V 01-01-2025
Subjects:	Brain development Erythropoietin Neonatology Neuroprotection Neonatology Neuroprotection Erythropoietin Brain development
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In addition to its hematopoietic function, erythropoietin (EPO) has demonstrated neuroprotective properties in preclinical studies, particularly in cases of reduced oxygenation or ischemia in the neonatal brain. While these findings have sparked optimism for its potential clinical application, the efficacy of EPO remains contentious in translational assays. Notably, while repeated administration of low doses of EPO has correlated with a decrease in adverse outcomes, the use of high EPO doses has shown either negligible or potentially detrimental effects on the incidence of brain injury. In this pilot study, we explored the effects of low and sustained doses of EPO (400 IU/kg) on the incidence of intraventricular hemorrhage (IVH) in premature infants. EPO was administered intravenously three times a week until the infants reached 32 weeks corrected gestational age. Our results indicate a significant decrease in the incidence of IVH with EPO treatment. Although, this study does not provide conclusive evidence on EPO's ability to reverse established IVH, these results strongly support the need for larger-scale clinical trials to further assess EPO's therapeutic potential. •Low and sustained doses of EPO prevent intraventricular hemorrhage in premature neonates.•EPO treatment reduces the odds of IVH by 97 % in premature newborns.•Our findings underscore the urgent need for larger clinical studies to definitively assess whether EPO has the potential to reverse established intraventricular hemorrhage in neonates
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1569-9048 1878-1519 1878-1519
DOI:	10.1016/j.resp.2024.104363